Format

Send to

Choose Destination
Nuklearmedizin. 2015;54(3):125-30. doi: 10.3413/Nukmed-0688-14-07. Epub 2014 Nov 25.

[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].

[Article in German]

Author information

1
Christina Lindner, MSc, Department Life Sciences, Medizinische und Pharmazeutische Biotechnologie, IMC FH Krems, E-Mail: ch.lindner@fh-krems.eu.

Abstract

There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists.

KEYWORDS:

Radioactive iodine-refractoriness; sorafenib; thyroid cancer

PMID:
25421138
DOI:
10.3413/Nukmed-0688-14-07
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center